Xilio Therapeutics Inc XLO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
-
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
-
Xilio Shares Take Flight Premarket After Gilead Deal
-
Xilio Therapeutics Plans Private Placement, Job Cuts
-
Gilead Sciences in Exclusive License for Xilio Tumor-Activated IL-12 Program
Trading Information
- Previous Close Price
- $0.75
- Day Range
- $0.73–0.81
- 52-Week Range
- $0.49–2.89
- Bid/Ask
- $0.73 / $0.77
- Market Cap
- $33.05 Mil
- Volume/Avg
- 126,154 / 143,206
Key Statistics
- Price/Earnings (Normalized)
- 0.18
- Price/Sales
- 11.17
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 73
- Website
- https://www.xiliotx.com
Comparables
Valuation
|
Metric
|
XLO
|
CLDX
|
PRLD
|
|---|---|---|---|
Price/Earnings (Normalized) | 0.18 | — | — |
Price/Book Value | 0.98 | 2.68 | 0.68 |
Price/Sales | 11.17 | 221.94 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
XLO
CLDX
PRLD
Financial Strength
|
Metric
|
XLO
|
CLDX
|
PRLD
|
|---|---|---|---|
Quick Ratio | 1.94 | 29.06 | 7.71 |
Current Ratio | 2.02 | 29.36 | 7.83 |
Interest Coverage | −326.66 | — | — |
Quick Ratio
XLO
CLDX
PRLD
Profitability
|
Metric
|
XLO
|
CLDX
|
PRLD
|
|---|---|---|---|
Return on Assets (Normalized) | −71.13% | −19.66% | −40.98% |
Return on Equity (Normalized) | −132.98% | −20.83% | −46.70% |
Return on Invested Capital (Normalized) | −103.20% | −20.72% | −44.57% |
Return on Assets
XLO
CLDX
PRLD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Fpqzmdzj | Scfc | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jfqhyjxq | Wyrzts | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lgvfwxs | Tkwpmj | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Svmwhjfmy | Dvfvf | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Nkjyprb | Jthm | $32.5 Bil | |||
| BioNTech SE ADR
BNTX
| Rqdkcxs | Kbst | $28.0 Bil | |||
| Moderna Inc
MRNA
| Yzmfxcyx | Gcs | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Fjglqbfw | Znrlt | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ymsjkfmx | Pntblz | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Rxdlptvkrk | Wcczl | $12.6 Bil |
United States